Videos
Examining a New Class of Antiretroviral Therapy for Patients With Multidrug-Resistant HIV-1 Infection
09/23/2020
Max Lataillade, DO, head of global research strategy, ViiV Healthcare, discusses the findings of the BRIGHTE study that demonstrated a significant decrease in HIV-1 RNA levels among patients treated with fostemsavir, a first-in-class investigational HIV-1 attachment inhibitor.
Disclosure:
The author reports no relevant financial relationships.
Reference:
Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, Grinsztejn B, Diaz R, Castagna A, Kumar P, Latiff G, DeJesus E, Gummel M, Gartland M, Pierce A, Ackerman P, Llamoso C, Lataillade M; BRIGHTE Trial Team. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2020 Mar 26;382(13):1232-1243. doi: 10.1056/NEJMoa1902493
Current Issue
September 2024
Volume 21
Issue 3
What's Trending?
Subscribe to our eNewsletters!
First Report Managed Care Newsletter